Compare F5 Inc (FFIV) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? F5 Inc trades at $460.11 (market cap $25.89B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: F5 Inc is far larger — about 2.9× Kymera Therapeutics Inc. Common Stock's market cap, and F5 Inc is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| FFIV | KYMR | |
|---|---|---|
Market Cap | $25.89B | $8.87B |
Volume | 575,445 | 779,107 |
Sector | Technology | Health |
52-Week High | $479.83 | $127.31 |
52-Week Low | $223.99 | $55.80 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | $24.54B | $8.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $476.24, up 0.58% today, showing strong momentum with three consecutive earnings beats and robust revenue growth to $3.09B in 2025. The stock exhibits bullish technical signals with moving averages supporting upward trends, while maintaining impressive profitability metrics including 81.87% gross margins and 21.95% net income margin. Recent recognition as a leader in IDC MarketScape for WAAP platforms and AI security innovations highlight continued market positioning strength.
Despite trading above analyst consensus target of $416.60, FFIV demonstrates solid fundamentals with expanding margins and strategic AI partnerships. Key risks include valuation premium at 36.44 P/E ratio and competitive pressures in application security. Institutional interest remains strong with BlackRock's significant position, supporting medium-term growth prospects amid evolving cybersecurity demands.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
